Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
05/2000
05/11/2000CA2348543A1 5ht1 receptor agonists and metoclopramide for the treatment of migraine
05/11/2000CA2348536A1 Radiodense compositions
05/11/2000CA2348446A1 Benzamide potassium channel inhibitors
05/11/2000CA2348267A1 Novel inhibitors of impdh enzyme
05/11/2000CA2347915A1 Enhanced radiation therapy
05/11/2000CA2347855A1 Use of a nicotine receptor agonist in the treatment of obsessive compulsive disorder
05/11/2000CA2347650A1 Transmembrane 4 proteins
05/11/2000CA2347119A1 Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
05/10/2000EP0998925A1 Medicinal compositions for topical administration containing vitamin d and vitamin k
05/10/2000EP0998916A1 Medicinal compositions for application to mucosa
05/10/2000EP0998914A1 Composition to enhance permeation of topical skin agents
05/10/2000EP0998585A1 SCREENING METHODS USING AN ATPASE PROTEIN FROM A VIRUS OF THE $i(FLAVIVIRIDAE) FAMILY
05/10/2000EP0998582A1 Methods for diagnosis and treating cancers, and methods for identifying pathogenic markers in a sample of normal cells
05/10/2000EP0998572A2 Aggrecan degrading metallo proteases
05/10/2000EP0998568A1 Mutant having uracil phosphoribosyl transferase activity
05/10/2000EP0998558A1 Wa545 compositions
05/10/2000EP0998495A1 Amyloid beta protein (globular assembly and uses thereof)
05/10/2000EP0998305A2 Cytolysis of target cells by superantigen conjugates inducing t-cell activation
05/10/2000EP0998300A1 Methods and compositions for modulating responsiveness to corticosteroids
05/10/2000EP0998298A2 Method of an increasing the antigen presenting ability of monocytes
05/10/2000EP0998295A1 The process for the preparation of a stable fixed dose pharmaceutical composition of anti infective agent/agents and micro organisms as active ingredients
05/10/2000EP0998294A1 Ganglioside gm3 induced apoptosis of neural cells
05/10/2000EP0998293A1 Cytokine related treatments of disease
05/10/2000EP0998292A2 Method for inhibiting bone resorption
05/10/2000EP0998291A1 Treatment of diabetes with thiazolidinedione and sulphonylurea
05/10/2000EP0998288A1 Compositions containing capsaicin or capsaicin analogues and a local anesthetic
05/10/2000EP0998278A1 Hydroxy and ether-containing oxyalkylene esters and uses thereof
05/10/2000EP0998274A2 Microdose therapy of vascular conditions by no donors
05/10/2000EP0998272A1 Pharmaceutical composition for combination of piperidinoalkanol-decongestant
05/10/2000EP0998263A1 Pyrrolidine derivative hair growth compositions and uses
05/10/2000EP0494224B1 Use of steroid hormones in compositions for inducing t cell lymphokine production
05/10/2000CN1252868A Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
05/10/2000CN1252727A Method and composition for treating sleep apnea
05/10/2000CN1252725A Analgesic combination
05/10/2000CN1252716A Inhibitor of leaderless protein export
05/10/2000CN1252689A Combined tumor suppressor gene therapy and chemotherapy in treatment of neoplasms
05/09/2000US6060588 Bap-1 proteins
05/09/2000US6060512 Method of using hydroxycarboxylic acids or related compounds for treating skin changes asociated with intrinsic and extrinsic aging
05/09/2000US6060499 Concurrently administering mixture of long-acting non-steroidal antiinflammatory drug (la-nsaid) with 5ht agonist to reduce relapse
05/09/2000US6060467 Graft survival prolongation with porphyrins
05/09/2000US6060454 Administering beta-blocker and atrioventricular node blocker to induce reversible ventricular asystole
05/09/2000US6060294 Alanyl tRNA synthetase from Staphylococcus aureus
05/09/2000US6060239 Cellubrevin homologs
05/09/2000US6060085 Dissolved drug that has the capacity to permeate the stratum corneum layer of the epidermis and become available systemically, and a drug in a microparticulate state that does not readily cross the stratum corneum
05/09/2000US6060047 Co-administration of interleukin-3 mutant polypeptides with CSF's for multi-lineage hematopoietic cell production
05/09/2000US6060037 Conjugated compounds which comprise an st receptor binding moiety and a radiostable active moiety
05/09/2000CA2151560C Insulin analog formulations
05/04/2000WO2000025138A2 Methods of diagnosing or prognosing alzheimer's disease
05/04/2000WO2000025137A1 Assays for autoantibodies
05/04/2000WO2000024911A2 Human phospholipases
05/04/2000WO2000024890A1 Novel g protein-coupled receptor proteins, dnas thereof and ligands to the same
05/04/2000WO2000024885A2 p53 MORPHOLINO-BASED ANTISENSE
05/04/2000WO2000024880A1 Transgenic c. elegans as a model organism for research into alzheimer's disease
05/04/2000WO2000024780A2 Compositions and methods for treating polycystic kidney disease
05/04/2000WO2000024771A2 Nucleic acids encoding osteoprotegerin-like proteins and methods of using same
05/04/2000WO2000024766A2 New transcription factor of mhc class ii genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
05/04/2000WO2000024761A1 Bile-acid substituted phenyl alkenoyl guanidines, method for the production thereof, use thereof as medicaments or diagnostic agents and medicaments that contain them
05/04/2000WO2000024758A1 ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF
05/04/2000WO2000024724A1 Thiazole-derivatives
05/04/2000WO2000024437A2 Textured and porous silicone rubber
05/04/2000WO2000024426A1 Ribozymes used as prodrugs
05/04/2000WO2000024419A1 Methods for enhancing wound healing
05/04/2000WO2000024410A1 Compositions and methods for treating benign prostatic hyperplasia using tocotrienols
05/04/2000WO2000024403A1 Use of antifungal agents for treating scleroses
05/04/2000WO2000024402A1 Use of antifungal agents for treating scleroses
05/04/2000WO2000024396A1 Treatment of disorders of the outer retina
05/04/2000WO2000024395A1 New use of glutamate antagonists for the treatment of cancer
05/04/2000WO2000024393A1 Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use
05/04/2000WO2000024391A2 Conductance of improperly folded proteins through the secretory pathway
05/04/2000WO2000024390A1 Method and composition for modulating amyloidosis
05/04/2000WO2000024383A1 Controlled-release pharmaceutical formulations containing a cgmp pde-5 inhibitor
05/04/2000WO2000024375A1 Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap
05/04/2000WO2000024374A1 Controlled release liquid delivery compositions with low initial drug burst
05/04/2000WO2000024366A1 Preparations for topical application of substances having antiandrogenic effect
05/04/2000WO2000024365A1 Treatment of skin with adenosine or adenosine analog
05/04/2000WO2000012139B1 Hypoxia regulated genes
05/04/2000WO2000012072A3 The use of fumaric acid derivatives in transplant medicine
05/04/2000WO2000006730A3 Human cytoskeletal proteins
05/04/2000WO2000006579A3 Pyrrolo[2,1-b][1,3]benzothiazepines with atypical antipsychotic activity
05/04/2000WO2000006187A3 Modulation of apoptosis
05/04/2000WO2000006139A3 Use of moclobemide and metabolites for treating and preventing substance abuse
05/04/2000WO2000006082A3 Treatment of anxiety disorders
05/04/2000WO1999064038A9 Novel analgesic agents
05/04/2000WO1999064031A9 β2-ADRENERGIC RECEPTOR AGONISTS
05/04/2000WO1999062315A3 Method for altering the activity of proteins of the pka signaling pathway
05/04/2000DE19849722A1 Substituierte Phenyl-alkenoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament Substituted phenyl alkenoylguanidine, processes for their preparation, their use as a medicament or diagnostic, and medicament containing them
05/04/2000CA2349523A1 Bile-acid substituted phenyl alkenoyl guanidines, method for the production thereof, use thereof as medicaments or diagnostic agents and medicaments that contain them
05/04/2000CA2348833A1 Human phospholipases
05/04/2000CA2348563A1 Compositions and methods for treating polycystic kidney disease
05/04/2000CA2348529A1 Conductance of improperly folded proteins through the secretory pathway
05/04/2000CA2348160A1 Use of antifungal agents for treating scleroses
05/04/2000CA2348019A1 Method and composition for modulating amyloidosis
05/04/2000CA2347828A1 Methods for enhancing wound healing
05/04/2000CA2347365A1 Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use
05/04/2000CA2347294A1 Novel g protein coupled receptor protein, dna and its ligand
05/04/2000CA2347293A1 Nucleic acids encoding osteoprotegerin-like proteins and methods of using same
05/04/2000CA2347068A1 New transcription factor of mhc class ii genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
05/04/2000CA2340225A1 Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap
05/04/2000CA2249648A1 Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity
05/03/2000EP0997153A1 Formulations for lipophilic compounds
1 ... 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 ... 1151